Home › Research › Brain tissue and pathology
A review on Alzheimer's disease pathophysiology and its management: an update
Kumar A, Singh A, Ekavali.. Pharmacological reports : PR, 2014-09-22
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Alzheimer's disease acknowledged as progressive multifarious neurodegenerative disorder, is the leading cause of dementia in late adult life. Pathologically it is characterized by intracellular neurofibrillary tangles and extracellular amyloidal protein deposits contributing to senile plaques. Over the last two decades, advances in the field of pathogenesis have inspired the researchers for the investigation of novel pharmacological therapeutics centered more towards the pathophysiological events of the disease.
What this study adds
Evidence grade: Low
This is a narrative review. This review describes the hallmark brain changes of Alzheimer's disease and notes that currently available treatments are acetylcholinesterase inhibitors such as rivastigmine, galantamine and donepezil, along with an N-methyl-D-aspartate drug. It reports that research has moved toward therapies aimed at the disease's pathophysiological events, but it presents no new treatment result.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Kumar, A., Singh, A., & Ekavali. (2015). A review on Alzheimer's disease pathophysiology and its management: an update. Pharmacological reports : PR. https://doi.org/10.1016/j.pharep.2014.09.004
Vancouver
Kumar A, Singh A, Ekavali. A review on Alzheimer's disease pathophysiology and its management: an update. Pharmacological reports : PR. 2015. doi:10.1016/j.pharep.2014.09.004. PMID: 25712639.
BibTeX
@article{kumar2015-25712639,
author = {Kumar, A. and Singh, A. and Ekavali},
title = {{A review on Alzheimer's disease pathophysiology and its management: an update}},
journal = {Pharmacological reports : PR},
year = {2015},
doi = {10.1016/j.pharep.2014.09.004},
pmid = {25712639},
url = {https://doi.org/10.1016/j.pharep.2014.09.004}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Pathologically it is characterized by intracellular neurofibrillary tangles and extracellular amyloidal protein deposits contributing to senile plaques.
- Over the last two decades, advances in the field of pathogenesis have inspired the researchers for the investigation of novel pharmacological therapeutics centered more towards the pathophysiological events of the disease.
- Currently available treatments i.e. acetylcholinesterase inhibitors (rivastigmine, galantamine, donepezil) and N-methyl d-aspartate receptor antagonist (memantine) contribute minimal impact on the disease and target late aspects of the disease.
- These drugs decelerate the progression of the disease, provide symptomatic relief but fail to achieve a definite cure.
Why it matters
This review describes the hallmark brain changes of Alzheimer's disease and notes that currently available treatments are acetylcholinesterase inhibitors such as rivastigmine, galantamine and donepezil, along with an N-methyl-D-aspartate drug. It reports that research has moved toward therapies aimed at the disease's pathophysiological events, but it presents no new treatment result.
Study details
- Evidence strengthLow
How this study scored 49/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 47 of the 96 points we could judge it on, which is 49 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Pharmacological reports : PR) |
| Journal's citation record | 1 / 4 | Pharmacological Reports: journal h-index 99 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2015 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 7 / 7 | Cited 1,574 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 121.1 citations a year over 13 year(s) since 2015 |
| Impact for its field and year | 6 / 6 | Cited 44.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 25 other studies in this library |
| Still being cited | 4 / 4 | Cited 310 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Ekavali holds only 3 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 0 / 3 | Panjab University: institution h-index 493 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 25712639) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 47 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 47 of the 96 points we could judge it on is 49 out of 100. |
| Total | 49 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 16.
Later studies that cite this one
25 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Brain tissue and pathology from nearby years
Also in Brain tissue and pathology
124 studies in the library are filed under Brain tissue and pathology with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Brain tissue and pathology hub.